Benign and polyclonal proliferation of immature T cells in a lymph node with preserved morphological architecture is called indolent T-lymphoblastic proliferation (iT-LBP). Although overall rare, they have been described in association with both benign and malignant disorders including Castleman disease. We report the first case of idiopathic multicentric Castleman disease associated with iT-LBP, all previous reports of iT-LBP in Castleman disease were unicentric. A 37-year-old-male presented with 3 months of fevers and B-symptoms and was found to have enlargement of multiple bilateral lymph node sites on both sides of diaphragm along with splenomegaly. Anemia, elevated C-reactive protein, hypoalbuminemia, and elevated interleukin-6 levels were present. Biopsy of a lymph node showed features suggestive of idiopathic multicentric Castleman disease and iT-LBP. Bone marrow biopsy was unremarkable. Siltuximab and steroids were used to treat the condition.

1.
Dispenzieri
A
,
Fajgenbaum
DC
.
Overview of Castleman disease
.
Blood
.
2020 Apr 16
;
135
(
16
):
1353
64
. .
2.
Ohgami
RS
,
Arber
DA
,
Zehnder
JL
,
Natkunam
Y
,
Warnke
RA
.
Indolent T-lymphoblastic proliferation (iT-LBP): a review of clinical and pathologic features and distinction from malignant T-lymphoblastic lymphoma
.
Adv Anat Pathol
.
2013 May
;
20
(
3
):
137
40
. .
3.
van Rhee
F
,
Voorhees
P
,
Dispenzieri
A
,
Fosså
A
,
Srkalovic
G
,
Ide
M
,
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease
.
Blood
.
2018 Nov 15
;
132
(
20
):
2115
24
. .
4.
van Rhee
F
,
Wong
RS
,
Munshi
N
,
Rossi
J-F
,
Ke
X-Y
,
Fosså
A
,
Siltuximab for multicentric Castleman’s disease: a randomised, double-blind, placebo-controlled trial
.
Lancet Oncol
.
2014 Aug
;
15
(
9
):
966
74
.
5.
Velankar
MM
,
Nathwani
BN
,
Schlutz
MJ
,
Bain
LA
,
Arber
DA
,
Slovak
ML
,
Indolent T-lymphoblastic proliferation: report of a case with a 16-year course without cytotoxic therapy
.
Am J Surg Pathol
.
1999 Aug
;
23
(
8
):
977
81
. .
6.
Kansal
R
,
Nathwani
BN
,
Yiakoumis
X
,
Moschogiannis
M
,
Sachanas
S
,
Stefanaki
K
,
Exuberant cortical thymocyte proliferation mimicking T-lymphoblastic lymphoma within recurrent large inguinal lymph node masses of localized Castleman disease
.
Hum Pathol
.
2015 Jul
;
46
(
7
):
1057
61
. .
7.
Fromm
JR
,
Edlefsen
KL
,
Cherian
S
,
Wood
BL
,
Soma
L
,
Wu
D
.
Flow cytometric features of incidental indolent T lymphoblastic proliferations
.
Cytometry B Clin Cytom
.
2020 May
;
98
(
3
):
282
7
. .
8.
Qian
YW
,
Weissmann
D
,
Goodell
L
,
August
D
,
Strair
R
.
Indolent T-lymphoblastic proliferation in Castleman lymphadenopathy
.
Leuk Lymphoma
.
2009 Feb
;
50
(
2
):
306
8
. .
9.
Ohgami
RS
,
Zhao
S
,
Ohgami
JK
,
Leavitt
MO
,
Zehnder
JL
,
West
RB
,
TdT+ T-lymphoblastic populations are increased in Castleman disease, in Castleman disease in association with follicular dendritic cell tumors, and in angioimmunoblastic T-cell lymphoma
.
Am J Surg Pathol
.
2012 Nov
;
36
(
11
):
1619
28
. .
10.
Woo
CG
,
Huh
J
.
TdT+ T-Lymphoblastic proliferation in Castleman Disease
.
J Pathol Transl Med
.
2015 Jan 15
;
49
(
1
):
1
4
. .
11.
Quesada
AE
,
Young
KH
,
Medeiros
LJ
,
Thakral
B
.
Indolent T-lymphoblastic proliferation associated with low grade follicular dendritic cell sarcoma and Castleman disease
.
Pathology
.
2018 Apr
;
50
(
3
):
351
2
. .
12.
Chauveau
B
,
Le Loarer
F
,
Bacci
J
,
Baylac
F
,
Dubus
P
,
Ling
C
,
[Indolent T-lymphoblastic proliferation in association with localized Castleman disease: A case report]
.
Ann Pathol
.
2019 Feb
;
39
(
1
):
29
35
. .
13.
Chen
J
,
Feng
J
,
Xiao
H
,
Ma
Q
,
Chen
Z
.
Indolent T-lymphoblastic proliferation associated with Castleman disease and low grade follicular dendric cell sarcoma: report of a case and review of literature
.
Int J Clin Exp Pathol
.
2019 Apr 1
;
12
(
4
):
1497
505
.
14.
Ohgami
RS
,
Sendamarai
AK
,
Atwater
SK
,
Liedtke
M
,
Fleming
MD
,
Natkunam
Y
,
Indolent T-lymphoblastic proliferation with disseminated multinodal involvement and partial CD33 expression
.
Am J Surg Pathol
.
2014 Sep
;
38
(
9
):
1298
304
. .
15.
Nathwani
BN
,
Kansal
R
,
Yiakoumis
X
,
Pangalis
GA
.
Indolent T-lymphoblastic proliferation: a name with specific meaning: reply
.
Hum Pathol
.
2015 Nov
;
46
(
11
):
1786
7
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.